**Aims and objectives of this session**
The aim of this session is to discuss on how to improve prostate cancer staging and outcomes after surgery.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**1057**  
**Lymphadenectomy trends in Gleason 7 prostate cancer: A population-based study**  
**By:** Chandrasekar T., Goldberg H., Klaassen Z., Hamilton R., Fleshner N., Kulkarni G.  
**Institutes:** University Health Network, Division of Urology, Dept. of Surgical Oncology, Toronto, Canada

**1058**  
**Population-based analysis: Changes in the natural history of low risk localized prostate cancer**  
**By:** Helgstrand J.T., 1 Klemann N., Toft B.G., Vainer B., Røder M., Iversen P., Brasso K.  
**Institutes:** 1Copenhagen University Hospital, Rigshospitalet, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, 2Copenhagen University Hospital, Rigshospitalet, Dept. of Pathology, Copenhagen, Denmark

**1059**  
**Non-prostate cancer mortality following radical prostatectomy or radiotherapy in men with localized and locally advanced prostate cancer: An analysis using propensity score matching**  
**By:** Kim S.I., Kim S.J., Choo S.H., Cho D.S.  
**Institutes:** 1Ajou University School of Medicine, Dept. of Urology, Suwon, South Korea, 2Bundang Jesaeng Hospital, Dept. of Urology, Seongnam, South Korea

**1060**  
**Oncologic long-term outcome in patients with pathologic Gleason 3+3 score at radical prostatectomy**  
**By:** Mandel P., Graefen M., Pompe R., Chun F., Salomon G., Huland H., Tilki D.  
**Institutes:** 1University Hospital Hamburg-Eppendorf, Martini-Clinic Prostate Cancer Center, Department of Urology, Hamburg, Germany, 2University Hospital Hamburg-Eppendorf, Martini-Clinic Prostate Cancer Center, Hamburg, Germany, 3University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

**1062**  
**Cost effectiveness comparison between neoadjuvant chemo-hormonal therapy and extended lymph node dissection in patients with high-risk prostate cancer**  
**By:** Hagiwara K., Hatakeyama S., Tobisawa Y., Yoneyama T., Imai A., Yoneyama T., Hashimoto Y., Koie T., Tsuchiya N., Habuchi T., Arai Y., Ohyama C.  
**Institutes:** 1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Yamagata University, Faculty of Medicine, Dept. of Urology, Yamagata, Japan, 3Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, 4Tohoku University Graduate School of Medicine, Dept. of Urology, Sendai, Japan

**1063**  
**Retrograde perfusion sphinterometry to evaluate efficacy of autologous 6-branch suburethral sling to properly restore sphincteric apparatus during robotic assisted radical prostatectomy (RALP)**  
**By:** Cestari A., Lolli C., Ghezzi M., Sangalli M., Zanoni M., Fabbri F., Sozzi F., Zanni G., Dell’Acqua V.,
1064

Transurethral catheter removal on postoperative day 2 after robot-assisted laparoscopic radical prostatectomy: A feasibility study from a single high-volume referral centre


Institutes: San Giovanni Addolorata Hospital, Dept. of Urology, Rome, Italy

1065

Visibility of characterized periprostatic nerve distributions for nerve-sparing radical prostatectomy

By: Sievert K-D.¹, Hennenlotter J.², Dillenberg T.², Kuehs U.², Wollner J.³, Kunit T.⁴, Zweers P.³, Andersson K-E.⁵, Pannek J.³, Amend B.²

Institutes: ¹Paracelsus Private Medical University of Salzburg, Dept. of Urology and Andrology, Salzburg, Austria, ²University of Tübingen, Dept. of Urology, Tübingen, Germany, ³Swiss Paraplegic Center, Dept. of Neuro-Urology, Nottwil, Switzerland, ⁴SALK, Dept. of Urology, Salzburg, Austria, ⁵Aarhus University, Dept. of Clinical Medicine, Aarhus, Denmark

1066

Oncological and functional outcome after radical prostatectomy in men ≤ 45 years of age


Institutes: University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center; Dept. of Urology, Hamburg, Germany

1067

A randomized control trial on the impact of regional hypothermia: Ad hoc analysis on short term recovery of sexual function after robot-assisted radical prostatectomy (RARP)

By: Ko Y-H.², Osann K.³, Skarecky D.¹, Morales B.¹, Ahlering T.¹

Institutes: ¹University of California, Irvine, Dept. of Urology, Orange, United States of America, ²Yeoungnam University, Dept. of Urology, Yeoungnam, South Korea, ³University of California, Irvine, Dept. of Medicine, Orange, United States of America

1068

The prognostic role of sentinel node dissection on biochemical recurrence-free survival rate of prostate cancer patients after robot-assisted radical prostatectomy

By: Grivas N.¹, Wit E.¹, Bex A.¹, Hendricksen K.¹, Horenblas S.¹, Kleinjan G.¹, Van Rhijn B.¹, Vegt E.², Van Der Poel H.¹

Institutes: ¹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute, Dept. of Nuclear Medicine, Amsterdam, The Netherlands

1069

Fluorescence supported lymph node dissection in robot-assisted radical prostatectomy – a prospective randomized clinical trial

By: Harke N.N.¹, Wagner C.², Schuette A.², Addali M.², Urbanan K.², Fangmeyer B.², Witt J.H.²

Institutes: ¹University of Rostock, Dept. of Urology, Rostock, Germany, ²St. Antonius Hospital, Prostate Center Northwest, Dept. of Urology, Pediatric Urology and Urologic Oncology, Gronau, Germany

17:00 - 17:07

Summary

D. Murphy, Melbourne (AU)